Aptose Biosciences Inc. Acquisition by Hanmi Pharmaceutical: Your Guide

1. What happened?

Here's the deal: Aptose Biosciences Inc. develops new treatments for blood cancers. Hanmi Pharmaceutical Co. Ltd., a major South Korean drug company, is buying Aptose. Hanmi plans to buy Aptose and make it a private company. They will add Aptose's drug pipeline to their own. This includes key programs like tuspetinib (TUS) for Acute Myeloid Leukemia (AML) and luxeptinib.

The big news is that Institutional Shareholder Services (ISS) has recommended this deal. ISS is an influential firm that advises shareholders on votes. ISS recommendations are very important. They often sway large investors. This signals the deal will likely happen. It also suggests it's good for shareholders. This acquisition fundamentally changes Aptose's future.

2. When did it happen?

This ISS recommendation news came out on March 19, 2026. Hanmi first announced its plan to buy Aptose on November 19, 2025. This started the formal process.

Shareholders will vote on this acquisition at a special meeting on March 31, 2026. This is fresh news. It leads up to a key vote. That vote will decide the company's future.

3. Why did it happen?

Companies don't usually make big changes like this without a reason.

Hanmi wants Aptose for strategic reasons. They likely want to grow their cancer drug pipeline. They also gain Aptose's clinical drugs and blood cancer expertise. This could also expand their market reach. For Aptose, the acquisition offers a clear path forward. It also provides immediate value for shareholders. ISS, the advisory firm, reviewed the deal. They decided it was good for Aptose's current shareholders. They noted a few key reasons for their recommendation:

• Good Price: The C$2.41 per share offer is a good price. It's a 28% premium over the stock's average. That average was C$1.88 in the 30 days before the deal was announced. This premium offers shareholders a substantial return compared to recent market valuations.
• Positive Market Reaction: The stock market reacted well to the initial announcement. Aptose's share price rose. This showed investors generally liked the deal terms.
• No Better Offers: ISS likely confirmed the Aptose board did its job. The board explored other options thoroughly. No other company offered a better deal. This was true during the period before the vote.
• Cash in Hand: Shareholders will receive C$2.41 in cash for their shares. This means certainty and immediate access to your money. This removes future market risks. It also removes uncertainty about drug development. Shareholders get a guaranteed return at the agreed price.

4. Why does this matter?

This is a pretty big deal for Aptose and anyone watching the company.

ISS, a respected independent voice, has recommended approval. This significantly increases the likelihood the acquisition will go through. If approved by shareholders and regulators, Aptose Biosciences will no longer be an independent, publicly traded company. Instead, it will become a private entity. It will operate as part of Hanmi Pharmaceutical. This means Aptose's shares will be delisted. Investors will no longer be able to buy or sell them publicly.

This changes Aptose's future path. It alters its operations and public perception. Aptose moves from an independent biotech. It becomes part of a larger drug company.

5. Who is affected?

• Investors (that's you!): If the deal is approved, you'll receive C$2.41 in cash for each Aptose share you own. This represents a 28% premium over the stock's average price of approximately C$1.88 in the 30 days before the initial announcement. This provides a clear exit strategy. It offers a guaranteed return at that price (assuming the deal closes). This brings certainty to an often volatile biotech market.
• The Company Itself: Aptose will cease to exist as a standalone public entity. Its drug development will continue under Hanmi. This includes new blood cancer treatments. Key drugs are tuspetinib (TUS) for AML and luxeptinib. This merger gives Aptose's drugs access to Hanmi's resources. These include more money, R&D power, and global markets. This could speed up drug development and sales.
• Employees: There could be shifts in management, company culture, and job roles. This happens as Aptose integrates into Hanmi's structure. Some roles might change. But joining a larger company offers stability. Employees could see more career chances and resources. This helps them advance Aptose's drug programs.
• Patients/Future Patients: Aptose's critical work on developing new cancer medicines will continue. This specifically targets blood cancers. Hanmi's support could help drugs like tuspetinib (AML) and luxeptinib. They might see faster clinical trials and more funding. This could create a stronger path to market. The goal is to get new treatments to patients sooner.

6. What happens next?

So, what's on the horizon?

The most immediate next step is the shareholder vote on March 31, 2026. Aptose's board has also unanimously recommended voting "FOR" the acquisition. They believe the deal is in shareholders' best interest. Shareholder approval usually needs two-thirds of votes. Then, Canadian courts must approve it. The Toronto Stock Exchange (TSX) must also approve delisting.

Once all necessary approvals are in place, the transaction will close. This will likely happen shortly after the shareholder vote. Aptose shareholders will receive their cash payment of C$2.41 per share. Aptose will then be delisted from stock exchanges. It will transition from a publicly traded company. It will become a private entity operating under Hanmi's control.

It's a period of adjustment and re-evaluation for the company. Its operations will integrate into Hanmi's larger drug business. They'll need to clearly communicate their new operational plan and strategic priorities post-acquisition.

7. What should investors/traders know?

Here's the practical stuff for you:

• The Vote is Key: The shareholder vote on March 31st is crucial. While ISS and the board recommend approval, it still needs to pass with the required majority (typically two-thirds of votes cast).
• Price Certainty (Mostly): If the deal closes, you'll get C$2.41 per share. The stock price might trade very close to this amount as the vote approaches. This reflects the high probability of the deal going through. The gap between the current stock price and the offer price is called the "arbitrage spread." This gap usually shrinks as the deal becomes more certain.
• No More Public Trading: If the acquisition is completed, Aptose stock will no longer be available to buy or sell on public exchanges. This means you won't see further stock price growth from Aptose alone. There will also be no more public financial reports.
• "Continuance" is Minor: The news also mentions a legal change called a "Continuance." This means moving the company's legal home from Canada to Alberta. This is often done for administrative efficiency. It can also take advantage of specific corporate law frameworks. ISS also recommended this. They noted it won't negatively impact shareholder rights. This is a technical detail, not a major concern for investors regarding the value of the acquisition.
• Stay Tuned: Keep an eye out for the results of the shareholder meeting. Also watch for any further announcements regarding the deal's closing. These will confirm the final timeline for receiving your cash payment.

Remember, this isn't financial advice, just an explanation. Always do your own research before making any trading decisions!